Sponsors
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Blog
Chairman, GDS International
Sales and the 'Talent Magnet'
A lot is written about being a ‘Talent Magnet’, either as a company, or as President. It’s all good practice – listen, mentor, reward, provide clear goals and career maps. Good practice for the employer, but what about the employee?26 May 2011
White Papers
Focus Area: Manufacturing
REACH out for better
As the industry raises the bar once again to protect human health and the environment against chemical substances, Ali S. Faqi discusses the implications of the REACH initiative for manufacturers of chemical substances.
Collaborative platforms key to future pharma success
Bringing together the worlds of the scientist, engineer, patient and payer will be increasingly important for future pharmaceutical success, argue Siemens’ Rebecca Vangenechten and Sivarama Nalluri. The linear rather than holistic relationship of R&D, manufacturing and patient hinders development and increases the time to market of new products. It also limits the ability of companies to make a reality of new opportunities for continuous manufacturing and prepare for a future of more personalised medicine.
Dr. Ali S. Faqi answers your questions about REACH
In this article, Ali S. Faqi discusses the implications of the REACH initiative for manufacturers of chemical substances. Dr. Faqi, DVM, PhD, DABT is Director of the Developmental and Reproductive Toxicology (DART) team and Senior Principal Study Director at MPI Research.
Supply chain analytics: pharma has to do better
The global pharma industry is currently weathering a storm of unprecedented market conditions. Accenture research has found that over the past five years, patent protection has expired on products accounting for more than US$80 billion (€60 billion) in annual sales, and in spite of steadily rising R&D costs, pipelines have failed to deliver replacements.
Small is beautiful – the future of SMEs in pharmaceutical development
In the ever-changing landscape that is pharmaceuticals, small truly is beautiful.
Source: www.ngpharma.com© 2012 GDS Publishing Ltd. All rights reserved.